The Neural-Interface Review That Refuses to Conclude

GENEVA — The review will not end, and this week its administrators explained why with unusual candor: every dataset they open raises a new one. The safety examination of Somaform Augmetics' neural-interface line, ongoing and contested across all of this year, remains formally open — not cleared, not concluded, not withdrawn — as regulators weigh long-term reports against a technology adopted by more than five percent of humanity. "We are not permitted to be fast. We are only permitted to be right," said a review-panel scientist who asked not to be named ahead of publication, describing a caseload of individual accounts that resist statistical tidiness. Julian Morrow, who founded the company and advocates for augmentation rights, has urged patience of a different kind, arguing the interface serves people who have few alternatives. Both are asking the public to wait. In Geneva this week, waiting looked less like inaction than like the refusal to sign a paper no one is yet sure of.